Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study.
Adult
Aged
Aged, 80 and over
Anemia, Aplastic
/ blood
Anemia, Refractory
/ drug therapy
Benzoates
Drug Substitution
Drug Tolerance
Female
Follow-Up Studies
Humans
Hydrazines
Male
Middle Aged
Platelet Count
Prospective Studies
Pyrazoles
Receptors, Fc
/ administration & dosage
Receptors, Thrombopoietin
/ agonists
Recombinant Fusion Proteins
/ administration & dosage
Retrospective Studies
Thrombopoietin
/ administration & dosage
Aplastic anemia
Eltrombopag
Romiplostim
Thrombopoietin receptor-agonists
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
11
05
2020
accepted:
07
08
2020
revised:
29
07
2020
pubmed:
3
9
2020
medline:
26
11
2020
entrez:
3
9
2020
Statut:
ppublish
Résumé
Eltrombopag (EPAG) and romiplostim (ROM), thrombopoietin receptor-agonists with demonstrated efficacy against aplastic anemia (AA) in prospective controlled studies, were authorized in Japan for use in adults with aplastic anemia in 2017 and 2019, respectively. So far, no data are available on the potential contribution of switching from ROM to EPAG or vice versa in terms of efficacy or tolerance. Efficacies and tolerance profiles of ten patients, who failed to respond to the maximum dose of EPAG and then switched to ROM, were evaluated. All ten patients received a maximum dose of ROM (20 μg/kg/week). At a median follow-up of twelve months, seven of ten patients (70%) had achieved either neutrophil, erythroid, or platelet response, including one complete response. No patients showed platelet count fluctuations that were reported during ROM treatment for immune thrombocytopenia. In univariate analysis of the relationship between efficacy and demographics, the response had a correlation with neither factors. None of the patients stopped the ROM treatment because of adverse events. Although a larger number of patients and a longer follow-up period are needed to confirm our findings, our results show the efficacy of ROM in patients with EPAG-refractory AA.
Identifiants
pubmed: 32876852
doi: 10.1007/s12185-020-02971-1
pii: 10.1007/s12185-020-02971-1
doi:
Substances chimiques
Benzoates
0
Hydrazines
0
Pyrazoles
0
Receptors, Fc
0
Receptors, Thrombopoietin
0
Recombinant Fusion Proteins
0
Thrombopoietin
9014-42-0
romiplostim
GN5XU2DXKV
eltrombopag
S56D65XJ9G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-794Références
Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–56.
doi: 10.1056/NEJMra1413485
Otha A, Nagai M, Nishina M, Shimada N, Nakao S, Kurokawa M. Incidence of aplatic anemia in Japan: analysis of data from a nationwide registration system. Int J Epidemiol. 2015;44:i178.
Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia 2013. Int J Hematol. 2013;97:564–72.
doi: 10.1007/s12185-013-1331-y
Baciglupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–36.
doi: 10.1182/blood-2016-08-693481
Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Blood Adv. 2018;2(21):3054–62.
doi: 10.1182/bloodadvances.2018020248
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.
doi: 10.1056/NEJMoa1200931
Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French reference center for aplastic anemia. Haematol. 2018;103(2):212–20.
doi: 10.3324/haematol.2017.176339
Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008;111(3):981–6.
doi: 10.1182/blood-2007-05-088500
Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopietin receptor agonists: ten years later. Haematol. 2018;104(6):1112–23.
doi: 10.3324/haematol.2018.212845
Khellaf M, Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematol. 2013;98(6):881–7.
doi: 10.3324/haematol.2012.074633
Zeigler FC, de Sauvage F, Widmer HR, Keller GA, Donahue C, Schreiber RD, et al. In vitro megakaryocytopoieteic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood. 1994;84:4045–52.
doi: 10.1182/blood.V84.12.4045.bloodjournal84124045
Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, El V, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27(2):424–30.
doi: 10.1634/stemcells.2008-0366
Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–25.
doi: 10.1182/blood-2013-10-534743
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540–50.
doi: 10.1056/NEJMoa1613878
Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019;6(11):e562–e572572.
doi: 10.1016/S2352-3026(19)30153-X
Drug label information of romiplostim in JAPAN. www.info.pmda.go.jp/go/pack/3999430D1024_1_06/?view=frame&style=XML&lang=ja Accessed May 1, 2020.
Killick SB. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207.
doi: 10.1111/bjh.13853
Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf Accessed May 1, 2020.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
doi: 10.1038/bmt.2012.244
Winkler T, Fan X, Cooper J, Desmond R, Young DJ, Townsley DM, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019;133(24):2575–85.
doi: 10.1182/blood.2019000478
Julian MJ, Daphne W, Yanli D, Joanne U, Valerie K, David C, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739–41.
doi: 10.1182/blood-2006-11-057968
Shida Y, Takahashi N, Nohda S, Hirama T. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther. 2011;42(1):11–20.
doi: 10.3999/jscpt.42.11
Gill H, Leung GMK, Lopes D, Kwong YL. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Br J Haematol. 2017;176:984–99.
doi: 10.1111/bjh.14024
Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51(6):842–56.
doi: 10.1177/0091270010375427
Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia(ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015;101:255–63.
doi: 10.1007/s12185-014-1731-7
Vlachodimitropoulou E, Chen YL, Garbowski M, Koonyosying P, Psaila B, Sola-Visner M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood. 2017;130(17):1923–33.
doi: 10.1182/blood-2016-10-740241
Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386–94.
doi: 10.1182/blood-2011-12-399667
Gonzalez-Porras JR, Mingot-Castellano ME, Andrade MM, Alonso R, Caparros I, Arratibel MC, et al. Use of eltrombopag after romiplstim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111–6.
doi: 10.1111/bjh.13266
Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2018;93(1):58–64.
doi: 10.1002/ajh.24935
Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88(2):402–9.
doi: 10.1182/blood.V88.2.402.bloodjournal882402
Zhao LP, De Fontbrune FS, Contejean A, Abraham J, Terriou L, Cecile C, et al. Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transplant. 2019;54:1161–3.
doi: 10.1038/s41409-019-0452-1
Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–71.
doi: 10.1182/blood-2008-04-150078